Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis
Non-randomised trial
OA: closed
CC0
⤵ 15 in-corpus citations
AI-generated summary
Danazol and leuprorelin acetate treatments both reduced serum CA-125 levels in women with endometriosis, with danazol showing a more sustained effect post-treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To investigate the effects of danazol and leuprorelin acetate on CA-125 levels during treatment for endometriosis.
PATIENTS AND METHODS: Fifty women with laparoscopically diagnosed and treated endometriosis, and 50 women without pelvic disease as a control group. Following surgical treatment, 35 women with endometriosis were divided into two groups. The first group (20 women) received 200 mg danazol three times daily for 6 months; the second group (15 women) received 3.75 mg leuprorelin acetate depot every 28 days for 6 months. Serum CA-125 levels were measured before medical treatment, during the last 15 days of the 6-month treatment course, and 3 months after treatment.
RESULTS: Serum CA-125 levels were significantly higher in women with endometriosis than in women in the control group. Before treatment, CA-125 levels in patients with stage III/IV endometriosis were significantly higher than those in stage I/II endometriosis. Six months of danazol or leuprorelin acetate depot treatment decreased serum CA-125 levels. Three months after stopping danazol, CA-125 levels remained significantly lower than pretreatment levels. On the other hand, 3 months after stopping leuprorelin acetate, CA-125 levels returned to pretreatment levels.
CONCLUSIONS: (a) Danazol and leuprorelin acetate are equally effective in the treatment of endometriosis. (b) Moreover, the results support the view that the determination of CA-125 levels may assist in evaluating progress of endometriosis treatment.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (15)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Blood biomarkers for the non-invasive diagnosis of endometriosis 2016
- Kuntai Capsule Inhibited Endometriosis via Inducing Apoptosis in a Rat Model 2016
- Endometriosis and possible inflammation markers 2015
- Serum markers for the noninvasive diagnosis of endometriosis 2015
- Theranekron for treatment of endometriosis in a rat model compared with medroxyprogesterone acetate and leuprolide acetate 2013
- ACUPUNCTURE IMPROVES THE EFFECTS OF CHINESE HERBAL MEDICINE IN TREATING ENDOMETRIOSIS MODEL RATS 2013
- Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment 2013
- Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women 2012
- Semi-invasive Diagnosis of Endometriosis Doctoral Thesis 2010
- Peripheral biomarkers of endometriosis: a systematic review 2010
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Effect of French maritime pine bark extract on endometriosis as compared with leuprorelin acetate 2007
- Efficacy of levamisole on experimental endometriosis 2007
- The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis 2006
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:02:35.474120+00:00
License: CC0
· commercial use OK